http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109071552-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate | 2017-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109071552-B |
| titleOfInvention | Degradation of cyclin dependent kinase 4/6(CDK4/6) by conjugation of CDK4/6 inhibitors to E3 ligase ligands and methods of use |
| abstract | The present application provides bifunctional compounds of formula (I) (I) Or a targeting ligand, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, that acts as a proteolytic degradation inducing moiety of cyclin dependent kinase 4(CDK4) and/or cyclin dependent kinase 6(CDK 6). The present application also relates to methods of targeted degradation of CDK4 and/or CDK6 by using bifunctional compounds that link ubiquitin ligase binding moieties to ligands capable of binding to CDK4 and/or CDK6, which can be used to treat disorders modulated by CDK4 and/or CDK 6. |
| priorityDate | 2016-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 456.